» Articles » PMID: 6136523

Characterization of the Optimal Stimulatory Effects of Graves' Monoclonal and Serum Immunoglobulin G on Adenosine 3',5'-monophosphate Production in FRTL-5 Thyroid Cells: a Potential Clinical Assay

Overview
Specialty Endocrinology
Date 1983 Oct 1
PMID 6136523
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Immunoglobulin G (IgG) preparations derived from the sera of patients with hyperthyroidism due to Graves' disease (TSAb) as well as a monoclonal IgG derived from heterohybridoma fusions of Graves' lymphocytes augmented cAMP levels in a continuous strain of functioning rat thyroid cells (clone FRTL-5) in culture. Optimal stimulation was the same for both types of IgG preparations when measured after 2 h of incubation with 5 X 10(4) cells/well and using cells maintained in a nongrowth, TSH-deficient medium for 7 days. At low IgG concentrations, the stimulatory activities of both preparations exhibited a linear dependence on concentration and similar Ka values (approximately 4 X 10(-8) M) despite the fact that 65% of the Graves' serum IgG preparations had a significantly better ability to inhibit TSH binding to membrane preparations. The Ka value for TSH in the same assay was about 5 X 10(-12) M. Using this cell assay, 90% of a series of hyperthyroid Graves' IgG preparations exhibited stimulating activity, a value comparable to the frequency of positive results found by ourselves and others using human thyroid cell and slice systems. In contrast, only 10% of patients who were euthyroid 1 yr after antithyroid drug withdrawal (n = 21) exhibited stimulating activity, and no stimulating activity was detected in patients with nontoxic nodular goiter (n = 11), toxic adenoma (n = 5), or thyroid carcinoma (n = 6). The studies suggest that an optimized rat FRTL-5 thyroid cell system is a clinically useful and convenient alternative to human thyroid cell and slice systems for detecting TSAbs.

Citing Articles

Comparison of a Novel Homogeneous Cyclic Amp Assay and a Luciferase Assay for Measuring Stimulating Thyrotropin-Receptor Autoantibodies.

Diana T, Olivo P, Chang Y, Wuster C, Kanitz M, Kahaly G Eur Thyroid J. 2020; 9(2):67-72.

PMID: 32257955 PMC: 7109431. DOI: 10.1159/000504509.


Insulin-like Growth Factor-I Receptor and Thyroid-Associated Ophthalmopathy.

Smith T, Janssen J Endocr Rev. 2018; 40(1):236-267.

PMID: 30215690 PMC: 6338478. DOI: 10.1210/er.2018-00066.


Bioassays for TSH Receptor Autoantibodies, from FRTL-5 Cells to TSH Receptor-LH/CG Receptor Chimeras: The Contribution of Leonard D. Kohn.

Giuliani C, Saji M, Bucci I, Napolitano G Front Endocrinol (Lausanne). 2016; 7:103.

PMID: 27504107 PMC: 4958915. DOI: 10.3389/fendo.2016.00103.


Concurrent overexpression of RET/PTC1 and TTF1 confers tumorigenicity to thyrocytes.

Endo T, Kobayashi T Endocr Relat Cancer. 2013; 20(6):767-76.

PMID: 24014739 PMC: 3796879. DOI: 10.1530/ERC-13-0310.


Novel chimeric thyroid-stimulating hormone-receptor bioassay for thyroid-stimulating immunoglobulins.

Lytton S, Li Y, Olivo P, Kohn L, Kahaly G Clin Exp Immunol. 2010; 162(3):438-46.

PMID: 21070207 PMC: 3026547. DOI: 10.1111/j.1365-2249.2010.04266.x.